Latest Peripheral Nerve Injury News

Page 1 of 1
Orthocell Limited reports growing adoption of its Remplir™ nerve repair product in nerve-sparing prostate cancer surgeries across Australia, positioning for a significant U.S. market expansion. The company is investing in research and commercial infrastructure ahead of a medium-term U.S. launch.
Ada Torres
Ada Torres
20 Nov 2025
ReNerve Limited’s innovative NervAlign® Nerve Cuff has secured approval for use across the US Department of Defense and Veterans Affairs healthcare systems, marking a major milestone for the Australian medtech company.
Ada Torres
Ada Torres
13 Nov 2025
ReNerve Limited is scaling up its clinical trial for the NervAlign® Nerve Cuff following promising interim results that show significant pain reduction in nerve repair patients. The expanded study aims to solidify evidence for broader regulatory approval and market adoption.
Ada Torres
Ada Torres
5 Nov 2025
ReNerve Limited reported a 38% increase in quarterly sales driven by the launch of its EmpliQ product range and ongoing development of advanced nerve repair technologies. The company’s cash position remains solid as it prepares for upcoming clinical trials.
Ada Torres
Ada Torres
23 Oct 2025
ReNerve Limited has achieved its first commercial sales of the EmpliQ™ amniotic tissue products, marking a significant step in its transition from R&D to commercialisation. The EmpliQ™ range complements its existing nerve repair solutions and targets a growing global wound care market.
Ada Torres
Ada Torres
14 Oct 2025
ReNerve Limited has launched its Empliq tissue product range in the US, marking a strategic expansion into the growing dermal and amniotic tissue market. The launch complements its existing nerve repair portfolio and sets the stage for further growth.
Ada Torres
Ada Torres
22 Sept 2025
ReNerve Limited has achieved a key milestone with its first sale and clinical use of a deep dermal tissue product in the US, broadening its surgical applications beyond nerve repair. This move complements its existing nerve repair portfolio and sets the stage for further product launches later this year.
Ada Torres
Ada Torres
18 Aug 2025
ReNerve Limited reported a robust 53% increase in annual revenue, driven by strategic partnerships and new regulatory approvals that broaden its global footprint in nerve repair.
Ada Torres
Ada Torres
30 July 2025
Orthocell has marked a pivotal milestone with the first US surgical use of its Remplir™ nerve repair device following FDA clearance, setting the stage for commercial expansion in a $1.6 billion market.
Ada Torres
Ada Torres
27 June 2025
ReNerve Limited reported a 39% sales increase in Q3 FY25 alongside compelling clinical validation of its NervAlign® Nerve Cuff and strategic international partnerships, positioning the company for broader market penetration.
Ada Torres
Ada Torres
29 Apr 2025
ReNerve Limited has reported a remarkable 260% increase in quarterly sales following its successful IPO, alongside strategic distribution deals in Hong Kong and the Middle East. The company is poised for further growth with upcoming clinical data and product developments.
Ada Torres
Ada Torres
29 Jan 2025